ArticleFrontiers in immunology2025
Targeted and personalized immunotherapy in lung adenocarcinoma: single-cell RNA sequencing of
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-small cell lung cancer (NSCLC) was a major cause of cancer-related mortality globally. Despite advancements in immunotherapy and targeted therapies, clinical outcomes were still limited by tumor heterogeneity and treatment resistance. The transcription factor (TF) FOS, a key component of the AP-1 complex, was linked to tumor progression and therapy resistance in various cancers, but its precise mechanisms remained unclear, and its role in lung adenocarcinoma (LUAD) was unknown. We investigated the tumor microenvironment (TME) of LUAD using single-cell RNA sequencing (scRNA-seq) to identify potential therapeutic vulnerabilities and Methods: We identified fourteen cell types by analyzing scRNA-seq data from LUAD samples (GSE164789) using Seurat (v4.4.0) and Harmony for batch correction. InferCNV was utilized to characterize the tumor cell subtypes after they were clustered using marker genes. CytoTRACE and Monocle were used to create pseudotime trajectories in order to map differentiation states. CellChat revealed intercellular communication networks, while SCENIC identified TF regulatory modules. The CCK-8, Edu, Transwell, and wound healing assays showed that Results: We discovered that invasive LUAD was dominated by a highly stem-like C0 Conclusion: Our studies show that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.